Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5365193 | 0.99 | HTR6 (0.46) | HTR6KCNH2ENPP3ENPP1ENPP2 | |
| SCHEMBL5767861 | 0.96 | HTR6 (0.49) | HTR6KCNH2ENPP3ENPP1ALDH1A1 | |
| SCHEMBL5770873 | 0.95 | HTR6 (0.48) | HTR6KCNH2ENPP3ENPP1ENPP2 | |
| Oxalic Acid SCHEMBL5372484 | 0.88 | HTR6 (0.57) | HTR6RORCHRH2 | |
| Oxalic Acid SCHEMBL5383148 | 0.85 | HTR6 (0.48) | HTR6RORCHRH2 | |
| Oxalic Acid SCHEMBL5379558 | 0.84 | HTR6 (0.47) | HTR6ENPP3ENPP1RORCHRH2 | |
| Oxalic Acid SCHEMBL5367236 | 0.84 | HTR6 (0.47) | HTR6HRH2 | |
| Oxalic Acid SCHEMBL5372564 | 0.84 | HTR6 (0.47) | HTR6RORCHRH2 | |
| SCHEMBL5769307 | 0.83 | HTR6 (0.61) | HTR6ALDH1A1RORC | |
| Oxalic Acid SCHEMBL5369658 | 0.83 | HTR6 (0.46) | HTR6RORCHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | FILLA SANDRA A | 2007-06-14 | — | — | US | disclosed |
| US-7230011-B2 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht6 receptor | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1377580-B1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | FILLA SANDRA ANN (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1377580-A2 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002060871-A2 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102481-A1 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | HTR6, HTR5A, TPH1 | HTR6 1/4885KCNH2 1001/4885ENPP3 880/4885 |
| US-20070135484-A1 | BENZENESULFONIC ACID INDOL-5-YL ESTERS AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR5A, HTR7 | HTR6 1/4885KCNH2 900/4885ENPP3 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.